answer text |
<p>The UK Patents Act 1977, in line with the WTO TRIPS Agreement, provides for compulsory
licenses in certain circumstances.</p><p> </p><p>Kadcyla (trastuzumab emtansine) is
currently available to patients in England for the treatment of HER2-positive locally
advanced, unresectable or metastatic breast cancer through the Cancer Drugs Fund.</p><p>
</p><p>The National Institute for Health and Care Excellence (NICE) is currently reviewing
its technology appraisal guidance on trastuzumab emtansine for refractory, HER2 positive
breast cancer. NICE expects to publish its updated guidance in February 2017.</p><p>
</p>
|
|